Ausgabe 1/2021
Inhalt (14 Artikel)
Emerging Therapies in Relapsed and Refractory Hodgkin Lymphoma: What Comes Next After Brentuximab Vedotin and PD-1 Inhibition?
Tamer Othman, Alex Herrera, Matthew Mei
High-Risk Mantle Cell Lymphoma in the Era of Novel Agents
Edward Nabrinsky, Alexey V. Danilov, Paul B. Koller
A New Target for Hodgkin Lymphoma - Camidanlumab Tesirine
Narendranath Epperla, Mehdi Hamadani
Targeted Therapies for Follicular Lymphoma
Jennifer Girard, Yasmin Karimi, Shannon Carty, Ryan Wilcox, Mark Kaminiski, Sami Malek, Tycel Phillips
Selecting the Optimal CAR-T for the Treatment of B-Cell Malignancies
Taha Al-Juhaishi, Sairah Ahmed
Lessons Learned Treating Patients with Multiple Myeloma in Resource-Constrained Settings
Guillermo J. Ruiz-Argüelles, David Gómez-Almaguer
When to Use Targeted Therapy for the Treatment of Follicular Lymphoma
Loretta J. Nastoupil
Joining Efforts for PTLD: Lessons Learned from Comparing the Approach and Treatment Strategies Across the Pediatric and Adult Age Spectra
Francesca Montanari, Manuela Orjuela-Grimm
AYA Considerations for Aggressive Lymphomas
Gabriela Llaurador, Lisa Giulino-Roth
Immunotherapies Old and New: Hematopoietic Stem Cell Transplant, Chimeric Antigen Receptor T Cells, and Bispecific Antibodies for the Treatment of Relapsed/Refractory Diffuse Large B Cell Lymphoma
Anupama Doraiswamy, Mansi R. Shah, Rajat Bannerji
Invited Review: Will Consolidation with ASCT Be a Thing of the Past for MCL and PTCL?
Alessandro Broccoli, Lisa Argnani, Pier Luigi Zinzani
An Update on the Clinical Evaluation of Antibody-Based Therapeutics in Acute Myeloid Leukemia
Sangeetha Venugopal, Naval Daver, Farhad Ravandi
Secondary AML Emerging After Therapy with Hypomethylating Agents: Outcomes, Prognostic Factors, and Treatment Options
Daniel R. Richardson, Steven D. Green, Matthew C. Foster, Joshua F. Zeidner
High-Dimensional Immune Monitoring for Chimeric Antigen Receptor T Cell Therapies
Sujata Sharma, David Quinn, J. Joseph Melenhorst, Iulian Pruteanu-Malinici